发明名称 イミダゾピリジン誘導体
摘要 The present invention relates to compounds of general formula wherein Ar is phenyl or pyridinyl; X1 is N or CH, X2 is N or CH, with the proviso that only one of X1 or X2 is N and the other is CH; R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, cyano or S(0)2-lower alkyl; R2 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen or cyano; n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.
申请公布号 JP6007339(B2) 申请公布日期 2016.10.12
申请号 JP20150544439 申请日期 2013.11.26
申请人 エフ.ホフマン−ラ ロシュ アーゲーF. HOFFMANN−LA ROCHE AKTIENGESELLSCHAFT 发明人 チェッカレッリ,シモーナ・エム;ヤーガジア,ラヴィ;ヤーコップ−ルートネ,ローラント;ヴィッヒマン,ユルゲン
分类号 C07D471/04;A61K31/437;A61P9/00;A61P25/00;A61P25/08;A61P25/14;A61P25/16;A61P25/18;A61P25/22;A61P25/24;A61P25/28;A61P25/32;A61P25/36;A61P27/02;A61P27/16 主分类号 C07D471/04
代理机构 代理人
主权项
地址